Tempus, a leader in Artificial Intelligence and precision medicine, has announced a suite of new features in its physician platform, Hub. Trusted by thousands of oncologists and care teams, Hub is an AI-enabled platform that provides access to patient insights in a secure environment. Tempus is now unveiling a collection of new and enhanced features designed to make it easier for clinicians to access each of their patient’s comprehensive profiles to better inform care.
Hub is accessible on both mobile and desktop for all physicians that order a Tempus test. The platform allows easy access to Tempus test orders and results, including guideline-matched therapies, treatment resistance information, clinical trial opportunities and longitudinal tracking of biomarkers for each patient. The new features and enhancements include:
- Patient similarities: This enhanced feature allows physicians to view other Tempus patients similar to their patient. Through Hub, providers can securely request de-identified patient reports through its secure platform to get a deep understanding about treatment plans, as well as easily connect with other providers for a second opinion.
- Consults: Within the Hub mobile application, users can use Consults, Tempus’ peer-to-peer messaging tool to easily discuss and collaborate with other physicians across institutions on complex patient cases. Consults provides instant de-identification of patient summary reports so that patient privacy is protected.
- Refresh: At any time after an initial test order, physicians can opt to ‘refresh’ a patient’s report results and receive updated therapies and clinical trials based on the latest information, rather than what was available at the time of the original order. This feature, which is currently being piloted, is designed to allow physicians to revisit a patient’s molecular profile findings and discover if new guidelines, therapies or clinical trials pertinent to that patient have become available.
- Tempus One updates: Tempus One now offers a ‘Concierge’ service embedded within Tempus One, which gives clinicians and care teams an easy way to request additional support from a Tempus team member. This high-touch feature gives users direct access to a Tempus team member to fulfill administrative requests such as supplemental testing, mobile phlebotomy, custom searches for sequenced patients by criteria, and more.
Physicians have the ability to query the Memorial Sloan Kettering Cancer Center OncoKB database to access the latest information on FDA-approved therapies and relevant biomarkers to help inform guideline-based care.
Continuously evolving to address clinical demands, Tempus One also now enables physicians to swiftly locate over 36 million citations and abstracts from PubMed’s biomedical literature and relevant publications.
“Hub has continuously evolved since we initially introduced it to physicians eight years ago, and as a result of their ongoing feedback and advancements in technology, we’ve honed the tool so that it seamlessly offers the power of our ordering solutions for physicians in one place,” said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. “Its versatility allows for physicians to use it however they prefer – whether it is to track a test order, report on how many of their patients have a singular biomarker or discuss a unique patient case with other treating physicians.”